Parabolic Drugs Issue Open Date 14-Jun-10   Issue Closing Date 17-Jun-10   Application Money 100   Allotment Money   Price Band 75 - 85   Minimium Application No. 80   Issue Size (Shares) 26666666   Market Lot 1   Objective The Net Proceeds of the Fresh Issue are proposed to be utilized by us for financing the following objects:1. Multi-purpose block III at Derabassi;2. Sterile cephalosporin plant at Derabassi;3. Establishment of Chachrauli plant;4. Custom synthesis and manufacturing site II at IT Park, Panchkula;5. Repayment / prepayment of identified loan facilities; and6. General corporate purposes. Category No. of Shares No. of Shares Subscription Ratio   Offered / Reserved Bid For   Non-Institutional Investors   3925000   4694960   1.20   Qualified Institutional Buyers   13083333   19343600   1.48   Retail Individual Investors   9158334   3658560   0.40   Business Description We were founded in 1996 by our Promoters Mr. Pranav Gupta and Mr. Vineet Gupta, who are professionally qualified first generation entrepreneurs. We are presently engaged in the manufacturing, including contract manufacturing, of APIs and API intermediates for the domestic market as well as for exports to international markets, including regulated markets. APIs, also known as =bulk drugs‘ or =bulk actives‘ are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients. We currently produce the Semi Synthetic Penicillin (?SSP?) and Cephalosporin range of antibiotics in oral and sterile form, along with their intermediates.We currently own and operate two manufacturing facilities at Derabassi, Punjab, and Panchkula, Haryana. We commenced commercial operations in February 1998 by setting up a unit at Sundhran, Derabassi, to manufacture SSPs. We currently have six units at Sundhran, Derabassi, for manufacturing the oral and sterile range of Cephalosporin APIs and intermediates. The facility at Sundhran, Derabassi, is WHO-GMP and ISO-14001 certified. We started our second facility at Panchkula in fiscal 2005. Currently, the Panchkula facility has two units manufacturing SSPs and API intermediates such as 6-APA. We are also in the process of setting up a custom synthesis and research and development (?R&D?) centre at Barwala, Haryana, for development and scale-up of new APIs and APIs intermediates in all therapeutic segments, including non-antibiotic products. This facility is expected to commence operations in the last quarter of fiscal 2010, to focus on providing contract research services to innovator companies. In addition, we are in the process of setting up another manufacturing facility at Chachrauli, Derabassi, to manufacture the non-antibiotic range of APIs, which is expected to commence commercial operations in the third quarter of fiscal 2011.Our product portfolio presently comprises 42 APIs and seven API intermediates which are marketed domestically and exported. We supply our products to approximately 45 countries, including regulated markets. We have filed 15 dossiers with the relevant regulatory authorities to increase our penetration in the regulated markets. This includes six DMFs filed with the USFDA, one DMF filed with the Bureau of Pharmaceutical Sciences, Canada and eight dossiers filed with the EDQM, including two for which we have received Certificates of Suitability (?CoS?) from the EDQM, for supplying Amoxicillin and Flucloxacillin Sodium for the European markets. Currently, we supply 6-APA from our Panchkula facility for the US markets conforming to the regulations prescribed by the USFDA.We have an established R&D setup which comprises chemical and analytical research laboratories at our facility at Sundhran, Derabassi. Our focus is on developing non-infringing processes for new molecules for expansion of our product portfolio, existing process improvements and production cost efficiencies. Our R&D department has led the Company to successfully launch additional sterile and oral products over the years. During fiscal 2010, products such as Ceftazidime, Cefotiam, Ceftizoxime and Cephalothin were launched to further widen our product range. We have made eight applications for process patents, of which seven patent applications have been filed with the Indian Patent Office, and one international process patent for manufacturing Cefuroxime Axetil filed under the PCT. As at December 31, 2009, our research team comprised 81 scientists, including 24 Ph.Ds. Our dedicated custom synthesis and R&D facility at Barwala, which is expected to commence operations in the last quarter of fiscal 2010 will be the centre of our research activities. The Barwala facility will also house a custom synthesis site and a pilot manufacturing plant (kilo lab) to provide CRAMS services to innovator companies.We seek to establish long term relationships with our customers and expand our business opportunities with them. As at March 31, 2009, we catered to 487 customers worldwide, including some of the leading generic companies in the world.Our total income has increased from Rs. 15,056.33 lacs in fiscal 2007 to Rs. 39,693.70 lacs in fiscal 2009, and our profit after tax has increased from Rs. 1,358.98 lacs to Rs. 2,109.20 lacs during this period. Our total income and profit after tax as at September 30, 2009 were Rs. 23,342.56 lacs and Rs. 1,241.23 lacs, respectively. Our net sales have increased at a CAGR of 62.50% from fiscal 2007 to fiscal 2009. Direct exports constituted 27.65% of our net sales in fiscal 2009, and 32.25% as at September 30, 2009. Back Address S C O 99 - 100 Top Floor Sector 17 - B Chandigarh , Punjab , 160017 Phone : +91-172-3914646/3914647 Email : Website : Registrar Link Intime India Pvt Ltd C-13 Pannalal Silk Compound L B S Marg Bhandup Mumbai Listed at BSE, NSE Lead Manager Avendus Capital Pvt Ltd. ICICI Securities Ltd Promoters Parabolic Infrastructure Pvt Ltd. PNG Trading Pvt Ltd. Pranav Gupta Vineet Gupta Promoter's Holding Total Share Capital 37251049 Offered to Public 26666666 Promoter's Holding (Pre-Issue) 100 Promoter's Holding (Post-Issue) 38.04